Ardelyx Inc Market Cap ($782.31 Million)
Market Cap & Net Worth: Ardelyx Inc (ARDX)
Ardelyx Inc market cap. Ardelyx Inc (NASDAQ:ARDX) has a market capitalization of $782.31 Million ($782.31 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9620 globally and #2677 in its home market, demonstrating a -5.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ardelyx Inc's stock price $3.03 by its total outstanding shares 258187572 (258.19 Million). Also see ARDX cash flow metrics for how efficiently the company converts equity into cash flow.
Ardelyx Inc Market Cap History (2015–2026)
Ardelyx Inc market cap history from 2015 to 2026. Data shows change from $4.68 Billion to $782.31 Million (-15.43% CAGR). Check ARDX live share price for real-time trading data and today's change.
Index Memberships
Ardelyx Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #276 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1022 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.04% | #162 of 263 |
Weight: Ardelyx Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ardelyx Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ardelyx Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ARDX shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
3.70x
Ardelyx Inc's market cap is 3.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.67 Billion | $24.03 Million | -$112.39 Million | 152.60x | N/A |
| 2017 | $1.70 Billion | $42.00 Million | -$64.34 Million | 40.57x | N/A |
| 2018 | $462.16 Million | $2.61 Million | -$91.30 Million | 177.27x | N/A |
| 2019 | $1.94 Billion | $5.28 Million | -$94.94 Million | 366.92x | N/A |
| 2020 | $1.67 Billion | $7.57 Million | -$94.31 Million | 220.64x | N/A |
| 2021 | $284.01 Million | $10.10 Million | -$158.16 Million | 28.13x | N/A |
| 2022 | $735.83 Million | $52.16 Million | -$67.21 Million | 14.11x | N/A |
| 2023 | $1.60 Billion | $124.46 Million | -$66.07 Million | 12.86x | N/A |
| 2024 | $1.31 Billion | $333.62 Million | -$39.14 Million | 3.92x | N/A |
| 2025 | $1.51 Billion | $407.32 Million | -$61.60 Million | 3.70x | N/A |
Competitor Companies of ARDX by Market Capitalization
Companies near Ardelyx Inc in the global market cap rankings as of November 1, 2026. Also see Ardelyx Inc (ARDX) total assets for a full breakdown of the balance sheet.
Key companies related to Ardelyx Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Ardelyx Inc (2015–2026)
Market capitalization of Ardelyx Inc from 2015 to today. Between 2015 and today, Ardelyx Inc's market cap moved from $4.68 Billion to $ 782.31 Million, with a yearly change of -15.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $782.31 Million | -48.03% |
| 2025 | $1.51 Billion | +14.99% |
| 2024 | $1.31 Billion | -18.23% |
| 2023 | $1.60 Billion | +117.54% |
| 2022 | $735.83 Million | +159.09% |
| 2021 | $284.01 Million | -83.00% |
| 2020 | $1.67 Billion | -13.79% |
| 2019 | $1.94 Billion | +319.27% |
| 2018 | $462.16 Million | -72.88% |
| 2017 | $1.70 Billion | -53.52% |
| 2016 | $3.67 Billion | -21.63% |
| 2015 | $4.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Ardelyx Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $782.31 Million USD |
| MoneyControl | $782.31 Million USD |
| MarketWatch | $782.31 Million USD |
| marketcap.company | $782.31 Million USD |
| Reuters | $782.31 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more